Merriman Curhan Ford downgrades DepoMed (Nasdaq: DEPO) from Buy to Neutral.

Merriman analyst says, "DepoMed is a little-known specialty biopharmaceutical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE